Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189177 | 1.00 | KYNU (0.46) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL57869 | 1.00 | KYNU (0.46) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL56888 | 0.91 | CASP1 (0.47) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL56936 | 0.91 | CASP1 (0.48) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL21189145 | 0.85 | CASP1 (0.46) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL21189147 | 0.85 | CASP1 (0.46) | KYNUCASP1ELANEPRTN3KLK1 | |
| SCHEMBL56584 | 0.85 | HDAC1 (0.52) | KYNUELANEPRTN3CTSL | |
| SCHEMBL21189273 | 0.85 | ALDH1A1 (0.43) | ELANEPRTN3ALDH1A1 | |
| SCHEMBL21189149 | 0.85 | ALDH1A1 (0.43) | ELANEPRTN3ALDH1A1 | |
| SCHEMBL21189148 | 0.85 | ALDH1A1 (0.43) | ELANEPRTN3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | KYOTO UNIVERSITY (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | KYOTO UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | HACL2, HAO2, HPD | KYNU 1549/4885CASP1 1294/4885ELANE 3823/4885 |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | HACL2, HAO2, HPD | KYNU 1549/4885CASP1 1294/4885ELANE 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.